Navigation Links
High-Dosage of Epirubicin and Cyclophosphamide may cause AML

Adjuvant chemotherapy with epirubicin and cyclophosphamide for early breast cancer// patients increased the risk of Acute myeloid leukemia or Myelodysplastic syndrome.

Recent study published in Journal of clinical oncology reports that early breast cancer patients undergoing chemotherapy with higher than standard cumulative doses of epirubicin and cyclophosphamide have an increased risk of developing Acute myeloid leukemia (AML) or Myelodysplastic syndrome (MDS).

This study was done by Dr. David Rogers and his team, in which they have proved that patients undergoing adjuvant therapy with higher than standard cumulative doses of epirubicin and cyclophosphamide for early stage of breast cancer are at increased risk of developing AML or MDS. It has been reported that though the long-term survival of these patients as increased following administration of these drugs, but the risk of developing secondary AML with or without MDS has been increased.

Epirubicin monitoring plan was started by Dr. Rogers collaboration with Gruppo Pfizer of Milan, Italy to undergo 19 randomized clinical trials for adjuvant therapy in early breast cancer, the study included 9796 patients started in early 1984, with follow up till 2001. In this follow-up study 30 patients developed AML/MDS. Both the cumulative doses of epirubicin and cyclophosphamide had independent risk factors for AML/MDS. Other factors such as age, radiotherapy, granulocyte colony stimulating factor and tamoxifen were not independently associated with AML/MDS.

Patients taking more than the standard cumulative dose of epirubicin was found to have an increased relative risk of 6.80. The standard dose of epirubicin was found to be 720 mg/m. For doses no higher than the standard dose, "the low risk of secondary leukemia does not differ significantly from the risk in patients not treated with epirubicin or who received hormonal therapy only," Dr. Rogers' team notes.

Both epi rubicin and cyclophosphamide were usually administered in combination and the 4760 patients who received the standard doses of epirubicin and cyclophosphamide (6300 mg/m), the 8-year cumulative probability of developing AML/MDS was 0.37%, compared with 4.97% of the 261 patients who received higher cumulative doses of both drugs.

"In clinical practice, the described regimens have a strong benefit to risk ratio," the authors conclude, "and patients and clinicians can be reassured that the risk of leukemia is likely to be low if the cumulative doses of these regimens are not exceeded."
'"/>




Related medicine news :

1. Kissing can cause Kaposi’s Sarcoma in AID
2. Kidney Stones - Interesting New Research implicates bacteria as its cause
3. Roller coasters – cause “Chronic Headache?
4. Starvation in pregnant women can cause heart disease to their children
5. And now they say infections can cause heart disease!!!!
6. And now they say infections can cause heart disease!!!!
7. Ticks may cause more diseases
8. Depression may cause delayed wound healing
9. Analgesic abuse - cause for chronic headache in children
10. Strong pain killers likely to cause miscarriage
11. Pressure on spine cause problems
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina Negrette, a ... more than a decade of experience in psychiatry, treating clients in diverse settings, ... eating disorders, psychotic and manic conditions, as well as those who were fighting ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... for its Product Innovation in the prestigious CEO World Awards®. The coveted annual ... new products and services, CEO case studies, corporate social responsibility, and milestones from ...
(Date:7/24/2017)... ... ... Engineers at the University of Maryland have invented an entirely new kind of ... the body uses. , In ordinary batteries the electrical energy, or current, delivered ... battery is generated by moving positive ions from one end to the other of ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS ... Institute (SLMBNI), part of Saint Luke’s Health System . Dr. Upadhyaya has ... Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., who has served ...
(Date:7/24/2017)... CA (PRWEB) , ... July 24, 2017 , ... Cosmetic ... spotlight doctors and the cosmetic surgeries they perform on a daily basis. , ... the cosmetic surgery procedures they specialize in at their practices. , When asked ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
(Date:7/5/2017)... 5, 2017 Pace Analytical, a company of over 2,000 employees and ... have acquired ESC Lab Sciences, further solidifying their position as the top American ... . ... and CEO of Pace Analytical ... out of Mt Juliet, TN , enhances Pace Analytical,s capability ...
(Date:6/30/2017)... 2017 In vitro diagnostics market firm Kalorama ... at least ten diagnostic companies have successfully completed financings.  ... and a loan facility.  The size of these financings ... Kalorama Information provides a monthly IVD Market Trends ... Center. "Diagnostics ...
Breaking Medicine Technology: